Navigo Proteins GmbH Industries
-
Medical / Health Care
-
Several of the Navigo-created, ready-to-go Affilin molecules against solid tumor targets are currently developed as protein-drug conjugates (PDCs), by combining them to a half-life extending module and an engineered toxin-carrying moiety. Compared to notoriously difficult-to-produce and inhomogeneous Antibody-Drug Conjugates (ADCs), Affilin®-based PDCs have clear advantages. They are easily assembled from a specificity-conferring...
The long-standing, successful use of radio-theranostics in imaging and therapy is based on targeting radiolabeled molecules to tumors or other diseased tissues. Over 10,000 hospitals worldwide use radioisotopes for in-vivo diagnosis or treatment, reaching around 35 million patients each year. The ideal cancer imaging tool is a homogenous conjugate with a precisely defined payload-to-carrier ratio, showing specific tumor-targeting with minimal side-effects and fast clearance.
Solid tumor-specific Affilin molecules are currently being evaluated as CAR-T ligands. Specifically, they were confirmed to be functionally expressed on the effector cell surface, mediate target cell-binding and effective target cell-killing in a dose-dependent fashion. Importantly they were just as effective as commonly used antibody fragments.
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing board.